Clinical Trials Logo

Uterine Neoplasms clinical trials

View clinical trials related to Uterine Neoplasms.

Filter by:

NCT ID: NCT03624712 Recruiting - Uterine Neoplasms Clinical Trials

Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms

Start date: January 2012
Study type: Observational

Evaluation of clinical, therapeutic and prognostic relevance of new experimental results as well as optimization of therapeutic models and development of a new algorithm for therapeutic plan and therapy in patients with uterine neoplasm

NCT ID: NCT03604653 Recruiting - Colorectal Cancer Clinical Trials

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Start date: May 15, 2018
Study type: Observational

Patients with primary peritoneal cancer or secondary peritoneal cancers from stomach, colorectal, appendiceal, and gynecological primary origin will be screened by pathology and staging to see if they are eligible to undergo cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). To be eligible for the study, patients must be over 18 years of age, have appropriate pathology and stage with disease confined to the peritoneal cavity, have a good performance status, have laboratory values that fall within safe ranges to undergo an operation and receive intraperitoneal chemotherapy. The chemotherapeutic agent and dose will be assigned based on pathological diagnosis in accordance with current standard of care. Surgery will be performed with the goal of removing all visible tumor that may require removal of adjacent organs. Once only microscopic disease is present, the chemotherapy will be delivered directly into the peritoneum via intraperitoneal hyperthermia and perfusion device. This will continue for 90 minutes. Patients will be followed for tumor response, survival, toxicity, complications, quality of life, and tumor markers. They will have regular follow up visits with the surgeon, undergo routine surveillance imagings, and receive follow up phone calls periodically.

NCT ID: NCT03586661 Not yet recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Start date: August 31, 2018
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating participants with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back. Niraparib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03583736 Suspended - Uterine Cancer Clinical Trials

Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Uterine Cancer

Start date: June 27, 2018
Phase: N/A
Study type: Interventional

This project aims to evaluate whether rapid first contact with the oncologist the same day or the next day after pathologic diagnosis contributes to a decreased time to treatment, decreased patient anxiety and increased patient satisfaction.

NCT ID: NCT03552471 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start date: July 12, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.

NCT ID: NCT03540407 Recruiting - Clinical trials for Cervical Carcinoma Stage III

Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.

Start date: January 7, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and endometrial adenocarcinoma. This is a phase II, prospective, randomized and double blind clinical trial, which will include 66 patients assigned to 2 treatment arms: 33 patients will receive conventional treatment, plus a placebo of the nutritional supplement and another 33 patients will receive along with the conventional treatment the Oncoxin-Viusid nutritional supplement produced by the Catalysis Laboratories of Spain. Patients will receive oral treatment throughout the onco-specific treatment and up to 3 weeks after completion.

NCT ID: NCT03508570 Not yet recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Start date: August 2018
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the safest combination dose of nivolumab and ipilimumab that can be given by an intraperitoneal (IP) infusion to patients with gynecologic cancers. An IP infusion is an injection of the study drugs into the abdomen. This is an investigational study. Nivolumab and ipilimumab are both FDA approved and commercially available for the treatment of many different types of cancer. However, they are not FDA-approved for the treatment of gynecological cancers. It is considered investigational to use the combination of ipilimumab and nivolumab in patients with gynecological cancers and to give these drugs by an IP infusion. The study doctor can explain how the study drugs are designed to work. Up to 48 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03460483 Enrolling by invitation - Lynch Syndrome Clinical Trials

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

Start date: March 30, 2018
Phase: N/A
Study type: Interventional

This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.

NCT ID: NCT03423082 Not yet recruiting - Cervical Cancer Clinical Trials

Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

Start date: September 2018
Phase: Phase 4
Study type: Interventional

18F Fluciclovine is a recently FDA- approved radiopharmaceutical for prostate cancer biochemical recurrence, which is only minimally eliminated by the kidneys and therefore the image interpretation is not affected by nonspecific urine activity in the ureters and bladder, which is advantageous for pelvic imaging. Recent literature suggests that Fluciclovine PET has diagnostic potential for a variety of solid tumors, thus, allowing new opportunities for noninvasive probing of glutamine metabolism and clinical use in patient management. Current literature indicates that amino acid transporters including that of glutamine are upregulated in endometrial and cervical cancer so that Fluciclovine PET may have clinical potentials. The hypothesis is that Fluciclovine PET provides better imaging properties and greater diagnostic confidence and accuracy than FDG PET does in pelvic malignancies. Given the lack of current clinical data, a pilot study providing a direct comparison of Fluciclovine PET with FDG PET is warranted. The investigators seek to conduct a pilot study with 10 subjects to evaluate the clinical utility of Fluciclovine PET for staging of cervical cancer and endometrial cancer. This research will compare the diagnostic performance of the research Fluciclovine PET/MRI with the standard-of-care FDG PET/CT as an exploratory endpoint.

NCT ID: NCT03422198 Recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer

Start date: January 17, 2018
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating patients with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells.